03:05am Thursday 21 September 2017

In very ill, probiotics don’t prevent ‘superbugs’ from colonizing intestinal tract ​

Washington University  The probiotic Lactobacillus rhamnosus GG (above) was no more effective than regular medical care in preventing the colonization of superbugs in the gastrointestinal tracts of critically ill patients, according to a pilot study by Washington University researchers.

Probiotics live microorganisms believed to help restore the balance of intestinal bacteria and increase resistance to harmful germs were given to patients twice daily for up to two weeks. But they were no more effective than not giving probiotics, the researchers report Aug. 27 in Infection Control & Hospital Epidemiology.

“Probiotic use is an intriguing topic,” said Jennie H. Kwon, DO, lead author of the study and a clinical researcher in the Division of Infectious Diseases. “With fewer therapies available to treat multidrug-resistant organisms, innovative methods to prevent or eliminate gastrointestinal colonization are necessary.” 

Drug-resistant “superbugs” pose a serious risk to hospitalized patients particularly those in ICUs — because the microbes increase the risk of hard-to-treat infections that can spread easily.

The pilot study followed 70 patients admitted to ICUs at Barnes-Jewish Hospital in St. Louis. Researchers studied whether the probiotic Lactobacillus rhamnosus GG could prevent the intestinal colonization of superbugs such as Clostridium difficile (C. diff), vancomycin-resistant Enterococcus (VRE) and Pseudomonas aeruginosa.

Patients were randomly assigned to receive probiotics and routine care or routine care alone. The researchers then monitored whether the microbes took up residence in the intestinal tract — a first step to developing a full-blown infection.

The data showed that the drug-resistant microbes colonized the intestinal tracts of 10 percent of patients in the probiotic group and 15 percent in the standard-care group — a difference that was not statistically significant.

However, Kwon emphasized the study’s limitations: small patient sample size, brief length of patient follow-up, and use of a single type and dose of probiotic. Additionally, the researchers confined the study to gastrointestinal bacteria and did not assess the possible impact of probiotics on preventing the colonization of superbugs in the stomach or the upper airway. 

“Although our findings suggest that probiotics do not help prevent gastrointestinal colonization with drug-resistant organisms in critically ill patients, further study is necessary in this field,” Kwon said.

To that end, Kwon is part of a Washington University research team evaluating probiotics in hospitalized patients who are not in ICUs.

 


The research is funded by the Centers for Disease Control and Prevention Epicenter grant U54CK000162.

Kwon JH, Bommarito KM, Reske KA, Seiler SM, Hink T, Babcock HM, Kollef MH, Fraser VJ, Burnham C-A D and Dubberke, ER. Randomized controlled trial to determine the impact of probiotic administration on colonization with multidrug-resistant organisms in critically ill patients. Infection Control & Hospital Epidemiology. Online Aug. 27, 2015.

Washington University School of Medicine’s 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children’s hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children’s hospitals, the School of Medicine is linked to BJC HealthCare.


Share on:
or:

Health news